Tarlatamab for extensive stage small-cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have extensive-stage SCLC (cancer that has spread or come back).
- You must be able to do daily activities with little or no help (ECOG score 0 or 2).
- You must have brain imaging (MRI) done, and any brain metastases must be stable or treated.
- You must have adequate organ function (kidney, liver, blood counts).
- You must provide tumor tissue from a previous biopsy or surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
This study collects blood samples from people with small cell lung cancer or neuroendocrine tumors who are being treated with tarlatamab. The goal is to learn more about how the drug works in the body.
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
This trial tests a new immunotherapy medicine called tarlatamab given as maintenance therapy after initial treatment for limited-stage small cell lung cancer. It aims to keep the cancer from coming back.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
Hear when a new Extensive Stage Lung Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.